Login to Your Account

Centocor Licenses AVEO RON Antibodies for Potential $555M+

By Tom Wall

Wednesday, June 1, 2011
AVEO Pharmaceuticals Inc. licensed exclusive worldwide development and commercialization rights to the company's preclinical antibodies targeting the RON (Recepteur d'Origine Nantais) receptor to Centocor Ortho Biotech Inc., of Horsham, Pa., a wholly owned subsidiary of Johnson & Johnson, for $15 million up front, as much as $540 million in milestones and double-digit royalties on worldwide net sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription